Skip to main content

Table 1 Change of the structural parameters of the retina according to study timepoints and genetic mutation analysis

From: Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results

Patient No

Genetic mutation

Eye

Horizontal EZW

Vertical EZW

Outer retinal thickness

T0

T1

T2

T0

T1

T2

T0

T1

T2

1

RHO

R

3.56

3.83

3.84

4.62

4.84

4.84

85.0

152.2

154.1

2

RP1

L

3.21

3.34

3.38

3.36

3.41

3.42

93.4

120.4

121.8

3

EYS

R

1.86

1.87

1.87

1.15

1.18

1.18

117.4

117.8

117.6

4

Unknown

L

3.93

4.14

4.12

2.72

2.74

2.74

118.2

145.4

145.6

5

RPGR

L

1.61

1.64

1.37

1.44

1.48

1.13

103.0

105.7

101.2

6

Unknown

R

2.74

2.75

2.77

2.49

2.51

2.51

129.0

131.9

132.4

7

C2ORF

R

4.01

4.09

4.10

4.02

4.08

4.11

116.0

126.3

126.6

8

USH2A

L

2.61

2.65

2.64

2.45

2.62

2.61

101.4

102.2

102.0

9

USH2A

L

3.91

3.98

3.98

3.92

3.96

3.96

79.2

135.6

134.4

10

RP1

L

3.90

3.99

3.98

3.86

3.92

3.91

105.0

111.8

110.9

11

PDE6B

R

3.87

3.87

3.86

3.71

3.70

3.69

92.2

128.7

127.8

12

USH2A

R

1.02

1.04

1.04

1.09

1.17

1.17

128.2

145.6

144.8

13

PDE6B

L

1.15

1.18

1.18

1.13

1.13

1.13

101.0

104.8

105.6

14

MERTK

R

2.23

2.25

2.25

2.08

2.12

2.12

100.4

110.0

110.1

15

PRPF3

L

2.18

2.22

2.23

2.14

2.20

2.21

84.8

120.0

122.8

16

RPGR

R

2.18

2.16

2.15

2.14

2.12

2.11

128.6

98.4

96.7

17

PDE6B

L

2.90

2.93

2.93

1.32

1.34

1.34

105.6

122.8

122.6

18

TULP1

L

1.42

1.48

1.48

1.25

1.25

1.25

89.0

94.8

96.0

19

USH2A

R

2.11

2.14

2.14

3.03

3.06

3.06

82.6

109.0

110.1

20

PDE6B

R

1.11

1.11

1.11

1.14

1.14

1.14

84.2

86.8

87.0

21

BBS2

R

1.15

1.18

1.18

1.06

1.08

1.08

85.2

97.0

97.3

22

PRPF3

L

2.49

2.49

2.49

2.26

2.26

2.26

86.0

116.0

115.7

23

RP1

R

2.51

2.51

2.51

2.54

2.54

2.54

91.0

91.6

91.0

24

RHO

L

3.18

3.24

3.24

3.21

3.34

3.35

118.2

152.4

152.6

25

RHO

L

3.26

3.28

3.28

3.14

3.16

3.16

106.0

132.8

132.7

26

PRPF3

L

2.11

2.17

2.22

2.29

2.34

2.34

109.3

122.0

122.1

27

Unknown

L

1.78

1.80

1.80

1.66

1.66

1.66

120.2

135.8

136.2

28

Unknown

R

1.66

1.65

1.65

1.38

1.37

1.37

116.0

122.8

120.7

29

EYS

R

1.48

1.48

1.47

1.51

1.50

1.50

117.0

117.0

116.8

30

RHO

L

4.71

4.98

5.02

4.79

4.86

4.91

110.0

140.4

141.7

31

RHO

R

4.90

4.90

4.90

3.96

3.96

3.96

101.0

106.0

106.3

RHO

L

4.71

4.70

4.70

4.00

3.98

3.98

96.9

101.3

101.0

32

CERKL

R

2.57

2.60

2.60

2.44

2.44

2.44

70.4

111.8

111.6

CERKL

L

1.98

2.00

1.98

1.87

1.87

1.86

72.6

112.4

112.0

  1. EZW ellipsoid zone width (mm), T0 (baseline) just before the Wharton jelly-derived mesenchymal stem cell injection, T1 6th month after injection, T2 12th month after injection